Learn more The iShares Core High Dividend ETF (NYSEMKT: HDV) isn't as large or as popular as other dividend ETFs. As a result ...

Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...

That's an extremely healthy tape and we love to see it. While the gains of 2026 have obviously been in tech stocks away from ...

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism ...

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...

A U.S. senator is pressing pharmaceutical giant Merck over its patenting and pricing practices for the blockbuster cancer drug Keytruda, escalating congressional scrutiny of industry strategies that ...

Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...

Sen. Maggie Hassan is pressing pharmaceutical giant Merck over access and cost issues around one of its most popular and best ...

During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...

In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have ...

The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or ...